Can Birth Control Cause Headaches? What You Need to Know

When considering contraceptive options, patients and clinicians often weigh not only effectiveness but also side effects and tolerability. Headache is a commonly reported adverse effect of hormonal contraceptives and a frequent reason for changing methods. This article reviews the clinical evidence and mechanisms by which birth control may cause or modify headaches, describes how to distinguish contraceptive-related headaches from other headache disorders, outlines risk factors and contraindications, and provides practical management strategies for patients and clinicians.

Sources referenced include guidance and reviews from the American College of Obstetricians and Gynecologists (ACOG), the National Institutes of Health (NIH/MedlinePlus), Mayo Clinic, and Cleveland Clinic.

Understanding hormonal contraceptives and their actions

Hormonal contraceptives prevent pregnancy primarily by suppressing ovulation and altering endometrial and cervical mucus environments. They are available in multiple formulations and delivery routes; the hormonal composition and pharmacokinetics are relevant to their potential effects on headache.

Types of hormonal contraception:

Combined hormonal contraceptives (CHCs): contain both an estrogen (most commonly ethinyl estradiol) and a progestin. Available as:
Combined oral contraceptive pills (COCs)
Transdermal patch
Vaginal ring
Progestin-only methods:
Progestin-only pills (mini-pill)
Depot medroxyprogesterone acetate injection (DMPA)
Subdermal implants (e.g., etonogestrel implant)
Levonorgestrel-releasing intrauterine device (LNG-IUD)
Non-hormonal methods:
Copper intrauterine device (copper IUD)
Barrier and behavioral methods

Estrogen and progestin interact with multiple neurovascular systems. Estrogen, in particular, modulates vascular tone, neuronal excitability, serotonergic pathways, and inflammatory mediators implicated in migraine pathophysiology. Progestins have variable androgenic, estrogenic, and progesterone-receptor–mediated effects depending on the specific agent and dose.

(See ACOG, NIH, Mayo Clinic, Cleveland Clinic for clinical guidance on contraceptive options and risks.)

Types of headaches and how hormones influence them

Clinical categorization of headache types is essential because the relationship between hormonal contraception and headache differs by headache subtype.

Migraine (with or without aura): A primary headache disorder with recurrent attacks of moderate-to-severe unilateral or bilateral headache, often accompanied by photophobia, phonophobia, nausea, and sensitivity to movement. "Aura" refers to transient focal neurologic symptoms (visual disturbances, sensory changes) that typically precede the headache.
Tension-type headache: Typically bilateral, pressing or tightening quality, and milder intensity than migraine, often associated with stress, sleep disturbance, or muscle tension.
Estrogen-withdrawal headache: Headache triggered by a fall in estrogen levels; classically occurs in the hormone-free interval of cyclic hormonal contraceptive regimens or around the perimenstrual period.
New daily persistent headache (NDPH) and secondary headaches: Less commonly related to contraception; requires evaluation for underlying causes.

Hormonal fluctuations, particularly changes in estrogen level, are widely recognized triggers for migraine in susceptible individuals. Many patients report migraine worsening around the perimenstrual period (so-called menstrual migraine) because of the cyclic decrease in estradiol levels. By altering steady-state hormone exposure (e.g., with CHCs), contraception can either improve, worsen, or have no effect on headache frequency and severity, depending on the patient and the formulation.

(Reviewed in clinical resources and patient education materials: ACOG, Mayo Clinic, NIH.)

Can birth control cause headaches?

Short answer: Yes — hormonal contraception can cause or change headache patterns in some individuals. However, effects are heterogeneous: some patients experience new-onset headaches after starting a method, some have worsening of preexisting headaches or migraines, and others experience improvement or no change.

Common patterns observed clinically:

New-onset headaches after initiation: Some individuals develop headaches within weeks to months after starting hormonal contraception. This may represent sensitivity to the hormonal changes induced by the method.
Estrogen-withdrawal headache during pill-free intervals: Traditional 21/7 COC regimens (21 days active hormones, 7 days hormone-free) may precipitate headaches during the hormone-free interval when estrogen falls abruptly. Extended-cycle or continuous regimens that eliminate or shorten the hormone-free interval often reduce this pattern.
Worsening of migraine frequency or intensity: Some patients with preexisting migraine — particularly those with migraine without aura — may experience increased attacks after starting a CHC; conversely, others may report fewer attacks if cycles are suppressed.
Improvement with progestin-only or long-acting reversible contraception: Many patients see improvement in hormone-sensitive headaches with progestin-only methods (e.g., implant, LNG-IUD) or with continuous CHC regimens, although individual responses vary.
Method-specific differences: Patch and ring deliver steady hormones with different pharmacokinetics than pills and may have different effects on headache for individual patients.

Population-level data demonstrate variable associations. Observational studies and clinical reports confirm that hormonal contraceptives can be associated with headaches; however, causality is often difficult to establish because headache disorders are common in reproductive-aged people independent of contraception.

(For summary guidance on contraception and headaches, see ACOG and NIH resources.)

Mechanisms: how hormones can trigger or modify headaches

Biologic mechanisms linking hormones and headache include:

Serotonergic modulation: Estrogen influences central serotonin synthesis and receptor sensitivity. Fluctuations in estrogen may alter serotonin-mediated pain pathways implicated in migraine.
Vascular effects: Estrogen has vascular effects that modulate cerebral blood flow and vascular reactivity, potentially influencing migraine susceptibility.
Neuropeptides and inflammation: Estrogen affects levels of nociceptive peptides (e.g., calcitonin gene-related peptide [CGRP]) and inflammatory mediators involved in migraine pathophysiology.
Withdrawal phenomena: Sudden decreases in estrogen (e.g., during the pill-free week or after stopping combined contraceptives) can trigger headaches akin to menstrual migraine.

These mechanisms explain why both estrogen-containing and some progestin-dominant methods may influence headache patterns, and why stabilizing hormone levels (continuous dosing) or removing estrogen can alter symptoms.

(Physiological mechanisms described in migraine and reproductive endocrinology literature; see Mayo Clinic, ACOG.)

Clinical risk factors and contraindications

Certain patient factors increase the likelihood that hormonal contraceptives will adversely affect headaches or pose additional cerebrovascular risk.

Migraine with aura: CHCs are generally contraindicated in patients with migraine with aura because they increase the risk of ischemic stroke. This is emphasized in ACOG guidance and other major clinical recommendations. For patients with migraine with aura, progestin-only methods or non-hormonal contraception are preferred unless alternatives are exhausted and benefits outweigh risks.
Age and smoking: Women older than 35 who smoke have substantially increased cardiovascular risk with estrogen-containing contraceptives; smoking and age alone are contraindications for CHC use. If such patients also have migraine, risk assessment must be individualized.
Hypertension and vascular disease risk: Uncontrolled hypertension, known thromboembolic disease, or significant cardiovascular risk profile may preclude the use of estrogen-containing contraceptives.
Personal history of venous thromboembolism (VTE): Prior VTE is a contraindication to CHC use.
Breastfeeding and postpartum status: Estrogen-containing methods are generally avoided in early postpartum and while breastfeeding due to potential effects on milk production and VTE risk; progestin-only methods are preferred.
Adolescents and perimenopausal patients: Different risk–benefit considerations apply regarding bone health, menstrual regulation, and comorbid conditions.

(See ACOG practice statements and CDC Medical Eligibility Criteria for contraceptive use for specific contraindications and risk factors.)

Evaluation: when to suspect contraceptive-related headache and how to assess

A structured assessment helps determine whether headaches are related to contraceptive use or have another cause.

History:

Onset: When did headaches start relative to initiation or change of contraceptive method?
Pattern: Frequency, duration, location, quality, associated features (nausea, photophobia, phonophobia, aura symptoms such as transient visual disturbances or sensory changes), and triggers.
Temporal relation to cycle or contraceptive dosing: Are headaches clustered during pill-free intervals, during active hormone use, or continuous?
Prior headache history: Preexisting migraine or tension-type headaches and their baseline characteristics.
Medication and substance history: Use of analgesics (and risk of medication-overuse headache), SSRIs, triptans, or other agents.
Comorbidities and vascular risk factors: Hypertension, smoking, age, history of VTE, migraine with aura.
Impact: Functional impairment, missed work/school, and response to abortive therapies.

Physical and neurologic examination:

Vital signs (blood pressure)
Focused neurologic exam to identify focal deficits or signs suggestive of secondary causes

When to pursue diagnostic testing:

New-onset severe headache described as “thunderclap,” syncope, or neurological deficits — immediate evaluation and neuroimaging (CT/MRI) are indicated to exclude secondary causes (subarachnoid hemorrhage, intracranial hemorrhage, venous sinus thrombosis).
Progressive pattern with increasing severity or change in phenotype — consider neuroimaging.
Abnormal neurologic findings — urgency of further workup increases.

Keeping a headache diary for 6–12 weeks can aid in delineating patterns and temporal associations with contraceptive dosing.

(Clinical evaluation strategies are consistent with NIH/MedlinePlus and specialty neurology guidance.)

Management strategies: medical and contraceptive approaches

Management should be individualized and based on the headache phenotype, severity, patient preferences, and risk profile. Goals include minimizing headache frequency and severity, preventing secondary harms, and optimizing contraceptive efficacy and safety.

General principles:

If headaches are mild and tolerable, symptomatic treatment and observation may be reasonable initially.
If headaches are severe, disabling, progressive, or accompanied by aura in a patient using CHCs, change of contraceptive method and neurologic evaluation are often indicated.
If migraine with aura develops while on CHCs, immediate reconsideration of estrogen-containing contraception is recommended due to stroke risk.

Contraceptive adjustments:

Switch from combined estrogen–progestin methods to progestin-only methods if headache onset or worsening is temporally linked to estrogen exposure. Progestin-only options include the levonorgestrel IUD, etonogestrel implant, DMPA injection, or progestin-only pills.
Use continuous or extended-cycle CHC regimens (e.g., continuous daily active pills with no or minimal hormone-free interval) to prevent estrogen withdrawal headaches in those who tolerate the active formulation. Continuous dosing often reduces headache frequency related to cyclical estrogen decline.
Reduce estrogen dose for those with estrogen-related headaches (e.g., switch to a lower-ethinyl estradiol formulation), but note that very low estrogen doses may increase the likelihood of withdrawal headaches for some patients.
Consider the delivery route: transdermal patch and vaginal ring have different pharmacokinetics; some patients experience fewer symptoms with alternative routes, while others do not.
Nonhormonal contraception (e.g., copper IUD, barrier methods) may be appropriate when hormonal methods exacerbate headache and other options are contraindicated.
In patients with migraine with aura, avoid combined hormonal contraception; recommend progestin-only or nonhormonal options as first-line alternatives.

Pharmacologic acute treatments:

Nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen for mild-to-moderate attacks.
Triptans for moderate-to-severe migraine without contraindications (note: triptans are contraindicated with certain vascular disease).
Antiemetics for nausea.
Avoid overuse of analgesics to prevent medication-overuse headache.

Preventive pharmacotherapy:

Consider migraine prophylaxis when headaches are frequent or disabling despite acute therapy. Options include beta-blockers (propranolol, metoprolol), topiramate, amitriptyline, and other agents chosen based on comorbidities and patient factors.
Hormonal strategies (continuous CHC, short or no hormone-free interval) can serve as mechanical prevention when estrogen withdrawal is the mechanism.
In refractory cases, referral to a neurologist or headache specialist for advanced therapies (e.g., CGRP monoclonal antibodies, neuromodulation) may be required.

Bridging estrogen during hormone-free intervals:

For patients with predictable estrogen-withdrawal headaches, short-term estrogen supplementation (e.g., low-dose transdermal estradiol patch during the pill-free interval) has been used to prevent withdrawal headaches in select cases under specialist supervision.

Nonpharmacologic management:

Identify and mitigate triggers: sleep hygiene, regular meals, hydration, stress management, and avoidance of known dietary or environmental triggers.
Behavioral interventions: cognitive behavioral therapy, biofeedback, and relaxation techniques may reduce frequency and disability.
Lifestyle modifications: regular exercise, limiting caffeine, and smoking cessation.

Special considerations:

Breastfeeding: Progestin-only methods are preferred in the immediate postpartum period. Estrogen-containing methods can decrease milk production and carry increased VTE risk early postpartum.
Adolescents: Evaluate growth and bone health considerations with long-acting progestin (e.g., DMPA) vs. other options.
Perimenopause: Hormone fluctuations may compound headache patterns; individualized menopausal hormone therapy and contraceptive needs require specialist input.

(Clinical management references: ACOG guidance on contraception, NIH resources, Mayo Clinic and Cleveland Clinic patient education.)

When to discontinue or change a contraceptive method

Consider discontinuation or change of the contraceptive method in the following situations:

New-onset migraine with aura after starting CHCs.
Worsening of migraine frequency or severity that is disabling or unresponsive to reasonable acute and preventive measures.
Headaches that begin within days to weeks of starting a method and are temporally linked, especially if severe.
Development of contraindicating comorbidities (e.g., new hypertension, VTE, major vascular disease).
Patient preference due to intolerability or desire for alternative contraception.

When discontinuing an estrogen-containing contraceptive for headache concerns, counseling on alternative effective methods and immediate contraceptive needs is important. If the patient desires pregnancy, discuss timing and folic acid supplementation as indicated.

Special situations and examples

Patient with perimenstrual migraine that clearly worsens during the pill-free week: Consider continuous CHC dosing or extended-cycle regimens to suppress the hormone-free interval. If the patient has migraine with aura, avoid CHCs and consider progestin-only or nonhormonal methods.
Patient with new daily headaches after starting ethinyl estradiol–containing pill: Evaluate for other causes, keep a headache diary, consider switching to a progestin-only method, and refer for neurologic evaluation if severe or progressive.
Breastfeeding patient with migraine: Progestin-only methods (LNG-IUD, progestin-only pill, implant) are preferred. Estrogen containing products are generally deferred until breastfeeding is established.

When to seek urgent medical attention

Urgent evaluation is required for headaches with “red flag” features:

Sudden onset of severe headache (“worst headache of life” or thunderclap)
New focal neurologic deficits (weakness, aphasia, visual field loss, altered consciousness)
Progressive worsening or change from established headache pattern
Headache associated with fever, neck stiffness, or seizure
Headache in the context of severe hypertension or signs of stroke

In these scenarios, imaging and emergency evaluation are indicated regardless of contraceptive status.

Practical, stepwise approach for clinicians

Obtain a thorough headache history and neurologic examination. Use a headache diary to document patterns.
Assess timing relative to contraceptive initiation, changes, and dosing schedule.
Evaluate for red flags and vascular risk factors (migraine with aura, age >35 and smoking, hypertension, prior VTE).
For mild or tolerable headaches, consider symptomatic treatment and observation for a reasonable trial period (e.g., 2–3 months) while monitoring.
If headaches are temporally related to the hormone-free interval, consider extended-cycle or continuous CHC regimens or estrogen supplementation for selected patients without contraindications.
If headaches worsen or migraine with aura appears on CHCs, discontinue estrogen-containing contraception and switch to progestin-only or nonhormonal methods.
Implement acute and preventive headache therapies as clinically indicated, with referral to neurology or headache specialists for refractory or complex cases.
Provide counseling about the balance of contraceptive efficacy and potential neurologic risks, particularly in patients with migraine with aura.

Summary and key takeaways

Hormonal contraception can cause new headaches, worsen existing headaches, or, in some cases, improve them. The relationship is individualized and depends on the type of contraceptive, hormone dose and schedule, and the patient’s baseline headache disorder.
Estrogen fluctuations — especially abrupt declines during hormone-free intervals — are commonly implicated in migraine and other hormone-related headaches.
Migraine with aura is a significant contraindication to estrogen-containing contraceptives due to increased ischemic stroke risk; progestin-only and nonhormonal options are preferred in these patients.
Management strategies include adjusting the contraceptive method (switching to progestin-only, continuous dosing, or nonhormonal methods), employing acute and preventive headache therapies, and addressing lifestyle and trigger management.
Urgent evaluation is needed for headaches with red flag features, regardless of contraceptive use.

Patients experiencing bothersome headaches after starting or changing contraception should consult their healthcare provider to review symptoms, assess risk, and discuss alternative contraceptive and headache management options.

References and further reading

American College of Obstetricians and Gynecologists (ACOG). Combined hormonal contraception and migraine headaches. ACOG Patient FAQs and clinical guidance. Available at: https://www.acog.org/womens-health/faqs/combined-hormonal-contraceptives-and-migraine
Centers for Disease Control and Prevention (CDC). U.S. Medical Eligibility Criteria for Contraceptive Use. (Guidance on contraindications and special situations.) Available at: https://www.cdc.gov/reproductivehealth/contraception/mmwr/mec/summary.html
National Institutes of Health / MedlinePlus. Headache. Overview and patient education. Available at: https://medlineplus.gov/headache.html
Mayo Clinic. “Birth control and headaches: Can birth control cause headaches?” Patient information and expert answers. Available at: https://www.mayoclinic.org
Cleveland Clinic. Birth control and headaches — causes, management, and treatment considerations. Available at: https://my.clevelandclinic.org/health

(When making clinical decisions, consult the most current guidance and individualize care according to the patient’s medical history and preferences. The resources above provide accessible overviews and practice guidance from leading institutions.)